Shopping Cart
- Remove All
- Your shopping cart is currently empty
3-Deazaneplanocin A (DZNep) is a dual inhibitor of histone methyltransferase (EZH2) and S-adenosylhomocysteine hydrolase (AHCY) with antipoxidative activity that inhibits hepatic, renal, peritoneal, and airway fibrosis by inducing proteasomal degradation of its targets and reducing toxicity in animal models.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $159 | In Stock | |
5 mg | $427 | 7-10 days |
Description | 3-Deazaneplanocin A (DZNep) is a dual inhibitor of histone methyltransferase (EZH2) and S-adenosylhomocysteine hydrolase (AHCY) with antipoxidative activity that inhibits hepatic, renal, peritoneal, and airway fibrosis by inducing proteasomal degradation of its targets and reducing toxicity in animal models. |
Targets&IC50 | MIAPaCa2 cells:1 μM, non-small cell lung cancer (NSCLC) cell lines:0.08 to 0.24 μM |
In vitro | Under 1.0 μM 3-Deazaneplanocin A (DZNep) treatment, OCI-AML3 cells showed an increase in cell number at G0/G1 phase, indicating cell cycle arrest. 3-Deazaneplanocin A treatment for 48 hours was able to dose-dependently inhibit the colony-forming ability of OCI-AML3 and HL-60 cells in the concentration range of 200 nM to 2.0 μM. [1] In addition, 3-Deazaneplanocin A treatment for 72 hours significantly reduced the expression of EZH2 in several cancer cell lines (e.g., PANC-1, MIA-PaCa-2, and LPc006) by 48%, 32%, and 36%, respectively. Although 3-Deazaneplanocin A had a weak inhibitory effect on the proliferation of PANC-1 cells, it had a stronger inhibitory effect on MIA-PaCa-2 and LPc006 cells, with IC50 values of 1 μM and 0.1 μM, respectively.[2] In non-small cell lung cancer (NSCLC) cell lines, 3-Deazaneplanocin A also exhibited dose-dependent inhibition of proliferation with IC50 ranging from 0.08 to 0.24 μM.[3] |
In vivo | In the NOD/SCID mouse model, the median survival of acute myeloid leukemia (AML) mice was significantly prolonged in the treatment group with the combination of 3-Deazaneplanocin A and Panobinostat (PS) compared to the group with the drug alone and the control group. Specifically, 36 days for the control group, 42 days for PS, 43 days for 3-Deazaneplanocin A, and 52 days for the combination group. [1] In addition, administration of 20 mg/kg 3-Deazaneplanocin A to rats significantly reduced body weight during the first three days of treatment (2.0%, 4.9%, and 1.2% reductions, respectively), and suppressed the rate of body weight growth to 2.6% per day from the fourth day on. [4] |
Alias | DZNep, 3-Deazaneplanocin |
Molecular Weight | 262.27 |
Formula | C12H14N4O3 |
Cas No. | 102052-95-9 |
Smiles | O[C@H]1[C@H](N2C=3C(N=C2)=C(N)N=CC3)C=C(CO)[C@H]1O |
Relative Density. | 1.75 g/cm3 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 75 mM H2O: 80.00 mg/mL (305.03 mM), Sonication is recommended | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.